Treatment with a specific inhibitor of Bcl-2, ABT-199 (also known as Venetoclax) at 1 μM, EDIL3-mediated anoikis resistance (Figure 6E) and anchorage-independent tumor growth (Figure 6F) were completely blocked. The gene discussed is BCL2; the disease is neoplasm.